Recent developments for MetaVia include positive clinical trial data releases, patent portfolio expansions, capital raises, and corporate actions such as a reverse stock split.

• In November 2025, MetaVia presented new Phase 1 and pre-clinical data on DA-1726 showing favorable safety, tolerability, and meaningful reductions in body weight and waist circumference, along with superior lipid-lowering efficacy in a mouse model compared to a competitor [S1].
• In November 2025, positive data from the Phase 2a clinical trial of vanoglipel (DA-1241) demonstrated clinically meaningful improvements in glucose control, liver health, and plasma lipidomic profiles after 16 weeks of treatment [S1].
• In January 2026, MetaVia announced statistically significant positive results from an 8-week Phase 1 clinical trial cohort of DA-1726, showing robust early weight loss and improvements in metabolic markers with favorable safety [S1].
• In January 2026, the company closed a $9.3 million underwritten public offering including full exercise of the allotment option [N3].
• In February 2026, MetaVia strengthened its global intellectual property position for DA-1726 with 39 granted and pending patents providing protection through 2041 [N2][S1].
• In March 2026, MetaVia announced a global patent portfolio for vanoglipel with 48 granted and pending patents providing protection into 2035 [S1].
• In December 2025, MetaVia completed a one-for-eleven reverse stock split approved by stockholders [S1].
• MetaVia's stock price declined following the pricing of the January 2026 public offering [N4].
• The company has ongoing collaborations leveraging AI-driven drug discovery platforms to support development of vanoglipel [S1].

MetaVia has demonstrated positive clinical data for its lead candidates DA-1726 and vanoglipel, including statistically significant weight loss and metabolic improvements, which support the potential therapeutic value of these drugs. The company has secured extensive patent protection globally, which could provide a competitive advantage if the products reach commercialization. Recent capital raises, including a $9.3 million public offering, provide liquidity to support ongoing clinical trials. Collaborations leveraging AI-driven drug discovery platforms may enhance development efficiency. The company's focused pipeline in cardiometabolic diseases addresses significant unmet medical needs.

MetaVia has incurred substantial operating losses and negative cash flows since inception, with no revenue generated to date and substantial doubt about its ability to continue as a going concern within one year from the financial statement issuance date. The company depends on successful clinical development and regulatory approvals, which are inherently uncertain and costly. Manufacturing is exclusively outsourced to Dong-A ST, posing supplier risk. The company faces risks related to intellectual property, competition, and the ability to raise additional capital, which may result in dilution or operational disruptions. Failure to advance clinical programs or secure financing could materially impact the business.

MetaVia's moat is primarily based on its proprietary intellectual property portfolio, including 39 granted and pending patents for DA-1726 and 48 granted and pending patents for vanoglipel, providing protection through 2035 and 2041 respectively. The exclusive licensing agreements with Dong-A ST Co., Ltd. for these product candidates and manufacturing rights further strengthen its competitive position. The company's clinical-stage assets with positive early clinical data and its focus on novel dual-incretin and metabolic therapies contribute to its differentiation. However, as a clinical-stage biotech firm without commercial products or revenues, its moat is contingent on successful clinical development, regulatory approvals, and commercialization capabilities.

• Clinical Development Risk: MetaVia's product candidates are in early clinical stages with inherent uncertainties regarding safety, efficacy, regulatory approval, and successful commercialization.
• Financial Risk: The company has a history of net losses and negative cash flows, with substantial doubt about its ability to continue as a going concern without additional financing.
• Manufacturing Risk: Reliance on a single third-party manufacturer, Dong-A ST, for production of product candidates creates supply chain and operational risks.
• Intellectual Property Risk: While MetaVia holds patents and licenses, challenges in obtaining, maintaining, or defending intellectual property rights could affect competitive positioning.
• Market and Competitive Risk: The company operates in a competitive biotech sector with potential competing technologies and market developments that could impact its products' commercial viability.

• MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases, primarily metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
• The company has two main product candidates: vanoglipel (DA-1241) and DA-1726, both in clinical development stages.
• MetaVia has reported positive clinical data from Phase 1 and Phase 2a studies for DA-1726 and vanoglipel, including statistically significant weight loss, reductions in waist circumference, improvements in glucose control, liver health, and lipid profiles.
• The company holds a global intellectual property portfolio with granted and pending patents for DA-1726 extending through at least 2041 and for vanoglipel through at least 2035, exclusively licensed from Dong-A ST Co., Ltd.
• MetaVia completed a one-for-eleven reverse stock split in December 2025.
• The company has incurred significant operating losses since inception, with a net loss of $12.97 million for the year ended December 31, 2025, and an accumulated deficit of approximately $148.8 million as of that date.
• MetaVia had cash and cash equivalents of approximately $10.3 million as of December 31, 2025, with a current ratio of 1.93 and a cash ratio of 1.82, indicating liquidity to fund operations into the fourth quarter of 2026, including proceeds from a $9.3 million underwritten public offering closed in January 2026.
• Research and development expenses decreased to $6.8 million in 2025 from $21.6 million in 2024, reflecting reduced clinical trial activities.
• General and administrative expenses were $6.9 million in 2025, slightly lower than in 2024.
• MetaVia has not generated any revenue to date and does not expect to generate revenue in the foreseeable future.
• The company relies on third-party manufacturers, exclusively Dong-A ST, for production of its product candidates, which presents supplier risk.
• MetaVia plans to continue funding operations through equity offerings, debt financing, warrant exercises, collaborations, and licensing arrangements.
• The company faces substantial doubt about its ability to continue as a going concern within one year from the issuance of its consolidated financial statements, due to ongoing net losses and cash burn.
• MetaVia has legacy therapeutic programs in viral, neurodegenerative, and cardiometabolic diseases that are not currently being advanced and may be out-licensed or divested.
• The company has disclosed detailed R&D expense components, including direct costs related to clinical development, manufacturing, and licensing fees, as well as indirect costs such as employee compensation and consulting.
• MetaVia's clinical development activities are central to its business model, with significant uncertainty around timing, costs, and regulatory approvals.
• The company completed a $9.3 million underwritten public offering in January 2026, including full exercise of the allotment option.
• MetaVia's stock price was affected by the public offering pricing in January 2026.
• The company has ongoing collaborations leveraging AI-driven drug discovery platforms to support development of its product candidates.
• MetaVia's management and board have taken steps to adjust capital structure and financing to support ongoing clinical development.
• The company has disclosed risks related to manufacturing, regulatory approvals, intellectual property, and competition.
• MetaVia's financial statements and disclosures are detailed in its 10-K filed on March 26, 2026.